Skip to main content
. 2017 May 10;8(42):71563–71573. doi: 10.18632/oncotarget.17751

Figure 2. IL-35 suppresses colon cancer in a dose-dependent manner.

Figure 2

(A) Wound healing assay of DLD1 and HT-29 cells with different concentrations of rhIL-35 protein (0, 1, 10, 100 ng/mL). n = 3. *P < 0.05. (B) Cell invasion assay of DLD1 and HT-29 cells with different concentrations of rhIL-35 protein (0, 1, 10, 100 ng/mL). n = 3. *P < 0.05. (C) Analysis of colon cancer cell apoptosis following treatment of rhIL-35. DLD1 and HT-29 cells were treated at the indicated doses, harvested, and stained with Annexin V-FITC and 7-AAD. Annexin V-FITC-positive apoptotic cells were determined by flow cytometry. n = 3. *P < 0.05. (D) The survival rate of DLD1 and HT-29 cells treated with different concentrations of rhIL-35 (0, 1, 10, 100 ng/mL) were analyzed. n = 3. *P < 0.05. (E) The clone formation number of DLD1 and HT-29 cells treated with different concentrations of rhIL-35 (0, 1, 10, 100 ng/mL) were analyzed. n = 3. *P < 0.05. (F) The percentage of CD44+CD133+ cancer stem cells of DLD1 and HT-29 cells treated with different concentrations of rhIL-35 (0, 1, 10, 100 ng/mL) were analyzed. n = 3. *P < 0.05.